ArticleInternational journal of colorectal disease2004
Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Article in International journal of colorectal disease, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.World journal of gastroenterology · 2013Pooled it
- A systematic review of humoral immune responses against tumor antigens.Cancer immunology, immunotherapy : CII · 2009Pooled it
- Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.EBioMedicine · 2020Article
- Potential diagnostic value of serum p53 antibody for detecting colorectal cancer: A meta-analysis.Oncology letters · 2018Article
- Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.Surgery today · 2017Article
- Differential Immune Reactivity Pattern of SW48 and SW1116 Colorectal Cancer Cell Lines with Colorectal Cancer Patients Sera.Advanced biomedical research · 2017Article
- Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer.Clinical journal of gastroenterology · 2016Article
- Serum anti-p53 antibody as a tumour marker for colorectal cancer screening.Ecancermedicalscience · 2015Article
- Article
- Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.Surgery today · 2014Article
- Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.Surgery today · 2014Article
- Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.British journal of cancer · 2013Article
- Cancer prognostics by direct detection of p53-antibodies on gold surfaces by impedance measurements.Small (Weinheim an der Bergstrasse, Germany) · 2012Article
- Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.Surgery today · 2012Article
- Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.International journal of colorectal disease · 2008Article
- Autoantibodies as potential biomarkers for breast cancer.Breast cancer research : BCR · 2008Article
- Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.Cancer research · 2006Article
- p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.British journal of cancer · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsOverexpression of p53 protein in malignancies induces an immune response in some cancer patients. We investigated whether production of serum antibodies against p53 (p53-Ab) is associated with pathohistological parameters of colorectal carcinoma and whether p53-Ab can serve as a tumor marker during cancer treatment. PATIENTS AND
methodsSerum samples from 220 colorectal cancer patients during surgery and adjuvant chemotherapy and 42 healthy controls were tested for the presence of p53-Ab by ELISA. Expression of p53 protein in tumors was determined using mouse anti-human p53-Ab.
resultsSerum p53-Ab were detected in 18% of patients while all controls were negative. A strong correlation between p53-Ab production and p53 protein expression was observed: 70% of p53-Ab positive cases had tumors positive for p53 vs. 52% of p53-Ab negative cases. There was also a significant predominance of p53-Ab positive cases in Dukes' stages B and C over stage A. Although surgery alone reduced p53-Ab levels, decreases in p53-Ab titer became significant midterm through chemotherapy compared to both pre- and postoperative values and remained decreased until the completion of treatment.
conclusionThe presence of p53-Ab in sera of patients with colorectal cancer indicates tumors in more advanced histopathologic stages (Dukes' B, C). Due to low sensitivity (18%) p53-Ab are not recommendable as a preoperative marker for colorectal cancer. However, due to high specificity (100%), their monitoring after surgery and adjuvant chemotherapy has potential for early diagnosis of tumor relapse in p53-Ab positive cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.